Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

Journal:
The Lancet
Published:
Affiliations:
28
Authors:
29
Institutions Authors Share
Bristol-Myers Squibb, United States of America (USA)
5.035714
0.17
Biomedical Research Networking Center in Hepatic and Digestive Diseases (CIBEREHD), Spain
1.071429
0.04
Centrul de Oncologie Sf Nectarie Craiova, Romania
1.035714
0.04
Copernicus Hospital Gdańsk, Poland
1.035714
0.04
Medical University of Vienna (MUW), Austria
1.035714
0.04
Institute for Advanced Biosciences (IAB), France
1.035714
0.04
China Medical University Hospital (CMUH), Taiwan
1.035714
0.04
CHA Bundang Medical Center, South Korea
1.035714
0.04
National Cancer Centre Singapore (NCCS), Singapore
1.035714
0.04
MedStar Georgetown University Hospital, United States of America (USA)
1.035714
0.04
The University of Auckland, New Zealand
1.035714
0.04
Kindai University, Japan
1.035714
0.04
Cross Cancer Institute, AHS, Canada
1.035714
0.04
The University of Hong Kong (HKU), China
1.035714
0.04
University Medical Center Mainz, JGU, Germany
1.035714
0.04
Institute of Cancer of São Paulo (ICESP), Brazil
1.035714
0.04
National Cancer Center Hospital East, Japan
1.035714
0.04
Bordeaux Institute of Oncology (BRIC), France
1.035714
0.04
Nanjing Tianyinshan Hospital, China
1.035714
0.04
Erasme Hospital, Belgium
1.035714
0.04
Bradford Hill, Chile
1.035714
0.04
Clínica Universidad de Navarra (CUN), UNAV, Spain
0.535714
0.02
National Cancer Center (NCC), South Korea
0.535714
0.02
Myongji Hospital, South Korea
0.535714
0.02
Humanitas University, Italy
0.535714
0.02
IRCCS Humanitas Research Hospital, Italy
0.535714
0.02
Gregorio Marañon University Hospital, Spain
0.535714
0.02